The role of radiation therapy in the management of plasma cell tumors

Mill, William B.; Griffith, Rogers C.

doi:10.1002/1097-0142(19800215)45:4<647::aid-cncr2820450405>3.0.co;2-e

Cited by 136 publications

(80 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is in contrast to the study by Mill and Griffith, who reported better local control rates among patients who received >50 Gy, 17 and the findings of Tournier-Rangeard et al, who reported that doses 45 Gy improved local control among patients with extramedullary SP. 18 Similarly, Mendenhall and colleagues reported that radiation doses 40 Gy resulted in a local control rate of 94% compared with 69% in patients who received <40 Gy.…”

Section: Discussioncontrasting

confidence: 94%

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

100

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P ¼ .021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P ¼ .016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P ¼ .048 and P ¼ .29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P ¼ .274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis. Cancer 2011;117:4468-

show abstract

Section: Discussioncontrasting

confidence: 94%

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

100

View full text Add to dashboard Cite

show abstract

“…Fugwe 2 Overall survival ( ) and disease-free survival (-) for the ten patients with extramedullary plasmacytoma. (Kotner and Wang, 1972;Meyer and Schulz, 1974;Corwin and lindberg, 1979;Woodruff et al, 1979ab;Mill et al, 1980;Mendenhall et al, 1980;Harwood et al, 1981;Bush et al, 1981;Knowling et al, 1983;Greenberg et al, 1987;Frssica et al, 1989), whereas others have found that local failure can occur with doses greater than 6000 cGy in patients with EMP (Petrovich et al, 1977;Bush et al, 1981). Mendenhall et al (1980) (Knowling et al, 1983;Mayr et al, 1990 (Mayr et al, 1990;Jackson and Scarffe, 1990;Holland et al, 1992).…”

Section: Clinical Investigationmentioning

confidence: 99%

Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone

Shih¹,

Dunn²,

Leung³

et al. 1995

Br J Cancer

157

127

View full text Add to dashboard Cite

SniaryThe clinical features and response to therapy of 32 Chinese patients with localised plasmacytoma are presented, and a companson between extramedullary plasmacytoma (EMP) and solitary plasmacytoma of bone (SPB) is made. Twenty-two patients had SPB and ten had EMP, accounting for 9% of all of our plasma cell neoplasms. Both groups had a male predominance with a median age of 54 years for SPB and 63 years for EMP. The common sites of SPB included vertebral bodies (15) and the skull (4). Most EMPs occurred in the oronasopharynx (6) and paranasal sinuses (2). An M-protein was detected in eight patients with SPB and in six with EMP. Seventeen patients with SPB and seven with EMP received radiation therapy, and all achieved initial local control. cies were evaluated at the division of Hematology-Oncology, Chang Gung Memorial Hospital, Taiwan. Of these patients, 32 had solitary plasmacytomas which were defined as (1) having a radiologically solitary lytic bone lesion or soft-tissue mass which was histologically proven to be a plasmacytoma, (2) less than 5% plasma cells in the bone marrow at diagnosis and (3) no anaemia, hypercalcaemia or impairment of renal function. Patients with M-protein in the serum or urine at presentation were not excluded from the study if they met the above criteria.

show abstract

“…The tumors may be either small or discrete, or they may grow to large dimensions. These lesions have a greater tendency to expand locally rather than to disseminate, a property that may be controlled by specific cytokines (Mill et al, 1980). The bone is probably the site of origin; however, they may arise from mucosa contained within the sphenoid and petrous bones, since non-osseous myelomas are common.…”

mentioning

confidence: 99%